{"filing":{"accession_number":"0001654954-26-008323","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"a5238u.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008323/a5238u.htm"},"events":[{"id":33119,"run_id":30445,"accession_number":"0001654954-26-008323","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This announcement discloses the failure of the SERENA-4 Phase III trial to meet its primary endpoint of statistically significant improvement in progression-free survival for Etcamah (camizestrant) in combination with palbociclib in first-line advanced ER-positive breast cancer. While a numerical improvement was observed, the trial did not achieve statistical significance. This is a material clinical development outcome affecting a key pipeline asset, but it is not a discrete event type (not an earnings release, M\u0026A activity, impairment charge, or litigation). It represents an operational/clinical milestone—specifically, a negative trial result—that would affect investor assessment of the company's oncology pipeline and the commercial prospects of Etcamah.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":36473,"accession_number":"0001654954-26-008323","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This announcement discloses the failure of the SERENA-4 Phase III trial to meet its primary endpoint of statistically significant improvement in progression-free survival for Etcamah (camizestrant) in combination with palbociclib in first-line advanced ER-positive breast cancer. While a numerical improvement was observed, the trial did not achieve statistical significance. This is a material clinical development outcome affecting a key pipeline asset, but it is not a discrete event type (not an earnings release, M\u0026A activity, impairment charge, or litigation). It represents an operational/clinical milestone—specifically, a negative trial result—that would affect investor assessment of the company's oncology pipeline and the commercial prospects of Etcamah.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T11:37:38.560751+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-14"}]}